Interleukin-18 promoter polymorphism is associated with lung cancer: A case-control study

References

• Blot WJ, McLaughlin JK. Are women more susceptible to lung cancer?. J Natl Cancer Inst 2004; 96: 812–3
   PubMedGoogle Scholar
• Moore R, Doherty D, Chamberlain R, Khuri F. Sex differences in survival in non-small cell lung cancer patients 1974–1998. Acta Oncol 2004; 43: 57–64
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88–91
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12: 53–72
   PubMed Web of Science ®Google Scholar
• Golab J. Interleukin 18–interferon gamma inducing factor–a novel player in tumour immunotherapy?. Cytokine 2000; 12: 332–8
   PubMed Web of Science ®Google Scholar
• Okano F, Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res 2000; 20: 3411–5
   PubMed Web of Science ®Google Scholar
• Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001; 167: 1644–53
   PubMed Web of Science ®Google Scholar
• Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006; 25: 417–34
   PubMed Web of Science ®Google Scholar
• Gunel N, Coskun U, Sancak B, Günel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 2002; 95: 663–7
   PubMed Web of Science ®Google Scholar
• Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: A possible role of polymorphisms in expression regulation. J Neuroimmunol 2001; 112: 146–52
   PubMed Web of Science ®Google Scholar
• Wei YS, Lan Y, Liu YG, Tang H, Tang RG, Wang JC. Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol 2007; 46: 1090–6
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin N, Huang L, Xu Q, Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 2007; 26: 613–8
   PubMed Web of Science ®Google Scholar
• Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C. Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res 2007; 27: 3849–53
   PubMed Web of Science ®Google Scholar
• Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, et al. Polymorphisms of interleukin [IL]-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 2004; 95: 672–9
   PubMed Web of Science ®Google Scholar
• Vairaktaris E, Serefoglou ZC, Yapijakis C, Agapi C, Vassiliou S, Nkenke E, et al. The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res 2007; 27: 4011–4
   PubMed Web of Science ®Google Scholar
• Asefi, V, Mojtahedi, Z, Khademi, B, Naeimi, S, Ghaderi, A. Head and neck squamous cell carcinoma (HNSCC) is not associated with interleukin-18 promoter gene polymorphisms, a case control study. J Laryngol Otol 2009;123:444–8
   PubMed Web of Science ®Google Scholar
• Khalili-Azad T, Razmkhah M, Ghiam AF, Doroudchi M, Talei AR, Mojtahedi Z, et al. Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma 2009; 56: 22–5
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
   PubMed Web of Science ®Google Scholar
• Folwaczny M, Glas J, Török HP, Tonenchi L, Paschos E, Bauer B, et al. Polymorphisms of the interleukin-18 gene in periodontitis patients. J Clin Periodontol 2005; 32: 530–4
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link?. Biochem Pharmacol 2006; 72: 1605–21
   PubMed Web of Science ®Google Scholar
• Lian H, Jin N, Li X, Mi Z, Zhang J, Sun L, et al. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and apoptin. Cancer Immunol Immunother 2007; 56: 181–92
   PubMed Web of Science ®Google Scholar
• Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Preclinical safety of recombinant human interleukin-18. Toxicol Pathol 2003; 31: 554–61
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, et al. Modulation of interleukin-18 expression in human colon carcinoma: Consequences for tumor immune surveillance. Int J Cancer 1999; 84: 326–30
   PubMed Web of Science ®Google Scholar